relatlimab nivolumab melanoma fda approval

Keyword Analysis

Keyword	CPC	PCC	Volume	Score	Length of keyword
relatlimab nivolumab melanoma fda approval	1.44	0.7	8614	33	42
relatlimab	0.69	0.8	4603	16	10
nivolumab	0.33	0.6	6184	58	9
melanoma	1.53	0.6	5391	77	8
fda	1.27	0.5	659	6	3
approval	0.66	0.9	7929	81	8

Keyword	CPC	PCC	Volume	Score
relatlimab nivolumab melanoma fda approval	0.35	0.8	2334	77
relatlimab nivolumab melanoma nejm	0.36	0.2	1467	28
nivolumab for metastatic melanoma	1.06	0.5	2135	65
nivolumab/relatlimab	1.82	0.1	8407	75
fda approval of nivolumab	0.26	0.5	8381	19
nivolumab immunotherapy for melanoma	1.24	0.9	6169	87
nivolumab and relatlimab-rmbw	0.49	0.4	1807	14
ipilimumab and nivolumab for melanoma	0.83	0.2	8285	44
nivolumab fda approval nsclc	1.46	0.1	4969	64
nivolumab and pembrolizumab for melanoma	1.86	0.8	6170	27
ipilimumab nivolumab combination fda approval	1.33	0.1	9894	16
nivolumab fda approval date	1.01	0.1	1128	46
pembrolizumab fda approval melanoma	1.37	0.4	1644	53
nivolumab fda label 2022	1.23	0.5	5764	88
ipilimumab and nivolumab metastatic melanoma	0.69	0.9	2812	12
pembrolizumab versus nivolumab for melanoma	0.67	0.7	9867	25
nivolumab ipilimumab nsclc fda	0.26	0.8	5056	50
formular terapeutic nivolumab melanom	0.76	0.4	5105	86
formular specific nivolumab melanom	0.42	0.7	6885	66